187 related articles for article (PubMed ID: 24300078)
1. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.
Vang DP; Wurz GT; Griffey SM; Kao CJ; Gutierrez AM; Hanson GK; Wolf M; DeGregorio MW
J Vis Exp; 2013 Oct; (80):e50868. PubMed ID: 24300078
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
[TBL] [Abstract][Full Text] [Related]
3. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K
Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745
[TBL] [Abstract][Full Text] [Related]
5. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
Kunze E; Schulz H; Adamek M; Gabius HJ
J Cancer Res Clin Oncol; 2000 Mar; 126(3):125-38. PubMed ID: 10741906
[TBL] [Abstract][Full Text] [Related]
6. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
7. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.
Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H
Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018
[TBL] [Abstract][Full Text] [Related]
8. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Becci PJ; Thompson HJ; Grubbs CJ; Squire RA; Brown CC; Sporn MB; Moon RC
Cancer Res; 1978 Dec; 38(12):4463-6. PubMed ID: 719631
[TBL] [Abstract][Full Text] [Related]
10. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.
Luo Y; Chen X; Han R; Chorev M; Dewolf WC; O'Donnell MA
J Urol; 1999 Oct; 162(4):1519-26. PubMed ID: 10492248
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M; Ramos KL; Andrade PM
J Exp Clin Cancer Res; 2008 Nov; 27(1):78. PubMed ID: 19040745
[TBL] [Abstract][Full Text] [Related]
12. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
[TBL] [Abstract][Full Text] [Related]
13. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
Degoricija M; Korac-Prlic J; Vilovic K; Ivanisevic T; Haupt B; Palada V; Petkovic M; Karaman I; Terzic J
J Transl Med; 2019 Nov; 17(1):394. PubMed ID: 31779626
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.
Akporiaye ET; Bradley-Dunlop D; Gendler SJ; Mukherjee P; Madsen CS; Hahn T; Besselsen DG; Dial SM; Cui H; Trevor K
Vaccine; 2007 Sep; 25(39-40):6965-74. PubMed ID: 17707958
[TBL] [Abstract][Full Text] [Related]
16. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.
Shiina H; Igawa M; Urakami S; Shigeno K; Yoneda T; Terashima M; Deguchi M; Ribeiro-Filho L; Dahiya R
Cancer Res; 2001 Oct; 61(19):7101-9. PubMed ID: 11585741
[TBL] [Abstract][Full Text] [Related]
17. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
18. The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Elkin M; Ayesh S; Schneider T; de Groot N; Hochberg A; Ariel I
Carcinogenesis; 1998 Dec; 19(12):2095-9. PubMed ID: 9886562
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors.
Grubbs CJ; Juliana MM; Eto I; Casebolt T; Whitaker LM; Canfield GJ; Manczak M; Steele VE; Kelloff GJ
Anticancer Res; 1993; 13(1):33-6. PubMed ID: 8476227
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Min W; Lee CC; Salim EI; Wanibuchi H; Sukata T; Fukushima S
Cancer Lett; 1999 Jan; 135(2):137-44. PubMed ID: 10096421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
